CollPlant Biotechnologies’ (CLGN) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of CollPlant Biotechnologies (NASDAQ:CLGN) in a research note released on Thursday,Benzinga reports. D. Boral Capital currently has a $14.00 price target on the stock.

Separately, HC Wainwright restated a “buy” rating and set a $11.00 target price on shares of CollPlant Biotechnologies in a research note on Friday, November 29th.

CollPlant Biotechnologies Stock Performance

Shares of CollPlant Biotechnologies stock opened at $2.55 on Thursday. The business has a 50-day simple moving average of $3.44 and a 200-day simple moving average of $3.93. CollPlant Biotechnologies has a one year low of $2.54 and a one year high of $6.75. The company has a market cap of $29.21 million, a PE ratio of -1.66 and a beta of 1.07.

CollPlant Biotechnologies (NASDAQ:CLGN) last announced its quarterly earnings data on Wednesday, March 26th. The company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.08. The company had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.36 million. CollPlant Biotechnologies had a negative net margin of 2,680.00% and a negative return on equity of 77.05%. On average, sell-side analysts predict that CollPlant Biotechnologies will post -1.44 earnings per share for the current fiscal year.

Institutional Investors Weigh In On CollPlant Biotechnologies

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC acquired a new position in shares of CollPlant Biotechnologies in the 4th quarter valued at $38,000. Wells Fargo & Company MN grew its position in CollPlant Biotechnologies by 110.1% during the 4th quarter. Wells Fargo & Company MN now owns 8,405 shares of the company’s stock worth $30,000 after purchasing an additional 4,405 shares during the last quarter. AMH Equity Ltd increased its stake in CollPlant Biotechnologies by 17.4% in the fourth quarter. AMH Equity Ltd now owns 116,500 shares of the company’s stock valued at $419,000 after purchasing an additional 17,295 shares during the period. Finally, Benjamin Edwards Inc. purchased a new stake in shares of CollPlant Biotechnologies in the third quarter valued at about $112,000. Hedge funds and other institutional investors own 21.69% of the company’s stock.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.